The National Heart, Lung, and Blood Institute's National @entity165 Education Program 2001 Adult Treatment @entity209 as having at least 3 of the following 5 criteria: @entity1144 , elevated @entity412 levels, low high-density lipoprotein @entity165 levels, an elevated blood pressure, and an elevated fasting @entity413 . Evidence is accumulating to suggest that the @entity209 predisposes to @entity65 ( @entity65 ). @entity454 ( @entity454 ) @entity1 requiring dialysis have a substantially elevated risk of @entity65 morbidity and mortality. Dialysis @entity1 ' increased risk can be partially explained by traditional and nontraditional risk factors. The prevalence of the @entity209 in dialysis @entity1 is unknown. This retrospective, cross-sectional study of 202 incident dialysis @entity1 examined the prevalence of the @entity209 at the time of renal replacement therapy initiation. The study group was compared with all incident dialysis @entity1 in 2002 on file with the U.S. Renal Data System. Females represented 39.1% of the study population. Blacks composed 34.7% of the study group. @entity6 was the etiology of @entity454 in 44.6% of our @entity1 . Surrogate criteria were used for the Adult Treatment Panel III risk factors of @entity1144 and elevated fasting @entity413 levels. Overall, the prevalence of the @entity209 was 69.3% in our population and was especially prevalent among @entity6 , female, and white @entity454 @entity1 . Study limitations included the use of surrogate markers for 2 criteria of the @entity209 and @entity734 on the Medical Evidence Report (Form 2728) for baseline characteristics. In summary, the @entity209 is highly prevalent in incident dialysis @entity1 .

Prevalence of the XXXX in an incident dialysis population.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetic'] @entity1144 :: ('MESH:D056128', 'Disease') :: ['abdominal obesity'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'Panel III report defined the metabolic syndrome'] @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['Cholesterol', 'cholesterol'] @entity454 :: ('MESH:D007676', 'Disease') :: ['End-stage kidney disease', 'ESKD']
@entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']
